HIV-1 infected patients have antibodies recognizing folded tat

Infectious Disorders - Drug Targets

Volumn 11, Issue 1, 2011, Pages 57-63

  Mediouni, Sonia ^a   Baillat, Gilbert ^a   Darque, Albert ^a   Ravaux, Isabelle ^a   Loret, Erwann ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Antibodies; HIV 1; Infected patients; Oyi; Tat; Vaccine

Indexed keywords

BUFFER; TAT HXB2; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; BLOOD SAMPLING; CONTROLLED STUDY; DOT HYBRIDIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MOLECULAR RECOGNITION; NONHUMAN; PH; PROTEIN ANALYSIS; PROTEIN STRUCTURE; PROTEIN VARIANT; SERUM; TRANSACTIVATION; UNFOLDED PROTEIN RESPONSE; VIRUS STRAIN;

EID: 79551649387     PISSN: 18715265     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152611794407737     Document Type: Article

References (24)

1. Fisher, A.G.; Feinberg, M. B.; Josephs, S. F.; Harper, M. E.; Marselle, L. M.; Reyes, G.; Gonda, M. A.; Aldovini, A.; Debouk, C.; Gallo, R. C.; Wong-staal, F. The trans-activator gene of HTLVIII is essential for virus replication. Nature, 1986, 320, 367-371.
2. Ensoli, B.; Barillari, G.; Salahuddin, S. Z.; Gallo, R. C.; Wong-Staal, F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature, 1990, 345, 84-86.
3. Campbell, G. R.; Loret, E. P. What does the structure-function relationship of the HIV-I Tat protein teach us about developing an AIDS vaccine? Retrovirology, 2009, 6, 50-63.
4. Gallo, R. C. Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine. Proc. Natl. Acad. Sci. USA, 1999, 96, 8324-8326.
5. Campbell, G. R.; Senkaali, D.; Watkins, J.; Esquieu, D.; Opi, S.; Yirrell, D. L.; Kaleebu, P.; Loret, E. P. Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties. Vaccine, 2007, 25, 8441-8447.
6. Senkaali, D.; Kebba, A.; Shafer, L. A.; Campbell, G. R.; Loret, E. P.; Van Der Paal, L.; Grosskurth, H.; Yirrell, D.; Kaleebu, P. Tatspecific binding IgG and disease progression in HIV type 1-infected Ugandans. AIDS Res. Hum. Retrovirus., 2008, 24, 587-594.
7. Opi, S.; Peloponèse, J. M.; Esquieu, D.; Campbell, G.; Mareuil, J.; Walburgert, A.; Solomiac, M.; Gregoire, C.; Bouveret, E.; Yirrell, D. L.; Loret, E. P. Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants. J. Biol. Chem., 2002, 277, 35915-35919.
8. Peloponese, J. M.; Gregoire, C.; Opi, S.; Esquieu, D.; Sturgis, J.; Lebrun, E.; Meurs, E.; Collette, Y.; Olive, D.; Aubertin, A. M.; Witvrow, M.; Pannecouque, C.; De Clercq, E.; Bailly, C.; Lebreton, J.; Loret, E. P. H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein. C R Acad. Sci. III, 2000, 323, 883-894.
9. Gregoire, C.; Peloponése, J. M.; Esquieu, D.; Opi, S.; Campbell, G.; Solomiac, M.; Lebrun, E.; Lebreton, J.; Loret, E. P. Homonuclear 1H-NMR assignement and structural characterization of human immunodeficiency virus type 1 Tat Mal protein. Biopolymers, 2001, 62, 324-335.
10. Watkins, D. J.; Campbell, R. G.; Halimi, H.; Loret, P. E. Homonuclear H NMR and circular dichroism study of the HIV-1 Tat variant. Retrovirology, 2008, 5, 83-94.
11. Shojania, S.; O'Neil, D. J. HIV-Tat is a natively unfolded protein. The solution conformation and dynamics of reduced Hiv-1 (1-72) by NMR spectroscopy. J. Biol. Chem., 2006, 281, 8347-8356.
12. Tahirov, T. H.; Babayeva, N. D.; Varzavand, K.; Cooper, J. J.; Sedore, S. C.; Price, D. H. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature, 2010, 465, 747-752.
13. Barany, G.; Merrifield, R. B. Solid phase peptide synthesis. In: The Peptide: Analysis, Synthesis, Biology. Gross, E.; Meinhofer, J., Eds.; New York, NY: Academic Press, 1980, vol 2, pp.1-284.
14. Péloponèse, J. M.; Collette, Y.; Gregoire, C.; Bailly, C.; Campese, D.; Meurs, E. F; Olive, D.; Loret, E. P. Full peptide synthesis, purification, and characterization of six Tat variants. J. Biol. Chem., 1999, 274, 11473-11478.
15. Koken, S. E.; Greijer, A. E.; Verhoef, K.; Wamel, J. V.; Bukrinskaya, A. G.; Berkhout, B. Intracellular analysis of in vitro modified HIV Tat protein. J. Biol. Chem., 1994, 269, 8366-8375.
16. Huet, T.; D'azza, M. C.; Brun-Vezinet, F.; Roelants, G. E.; Wain-Hobson, S. A highly HIV-1 strain isolated from a healthy Gabonese individual presenting an atypical western blot. AIDS, 1989, 3, 707-715.
17. Butto, S.; Fiorelli, V.; Tripiciano, A.; Ruiz-Alvarez, M. J.; Scoglio, A.; Ensoli, F.; Ciccozzi, M.; Collacchi, B.; Sabbatucci, M.; Cadaro, A.; Guzman, C.A.; Borsetti, A.; Caputo, A.; Vardas, E.; Colvin, M.; Lukwiya, M.; Rezza, G.; Ensoli, B.; Tat multicentric study group. Sequence conservation and antibody cross-recognition of clade B human immunodefisciency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J. Infect. Dis., 2003, 188, 1171-1180.
18. Tikhonov, I.; Ruckwardt, T. J.; S.Hatfield, G.; Pauza, C. D. Tat neutralizing in vaccinated macaques. J. Virol., 2003, 77, 3157-3166.
19. Mc Phee, D. A.; Kemp, B. E.; Cumming, S.; Stapleton, D.; Gus, I. D.; Doherty, R. R. Recognition of envelope and Tat protein synthetic peptide analogs by HIV positive sera or plasma. FEBS J., 1988, 233, 393-396.
20. Pattaramanon, N.; Sangha, N.; Gafni, A. The carboxy-terminal domain of Heat-Shock Factor 1 is largely unfolded but can be induced to collapse into a compact, partially structured state. J. Biol. Chem., 2007, 46, 3405-3415.
21. Uversky, V. N.; Gillespie, J. R.; Millett, I. S.; Khodyakova, A.V.; Vasilenko, R. N.; Vasiliev, A. M.; Rodionov, I. L.; Kozlovskaya, G. D.; Dolgikh, D. A.; Fink, A. L.; Doniach, S.; Permyakov, E. A.; Abramov, V. M. Zn2+-Mediated Structure formation and compaction of the "Natively Unfolded" Human Prothymosin α. Biochem. Biophys. Res. Commun., 2000, 267, 663-668.
22. Uversky, V.N.; Li, J.; Fink, A.L. Evidence for a partially folded intermediate in α-synuclein fibril formation. J. Biol. Chem., 2001276, 10737-10744.
23. Ugwu, S.O.; Apte, S. P. The effect of buffers on protein conformational stability. Pharma. Technol., 2004, 28, 1543-2521.
24. Virgin, H.W.; Walker, B. D. Immunology and the elusive AIDS vaccine. Nature, 2010, 464, 224-231.